Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise

Prandin, Maria Grazia; Cicero, Arrigo F G; Dormi, Ada; Veronesi, Maddalena; Cosentino, Eugenio Roberto; Borghi, Claudio

doi:10.1016/j.numecd.2009.05.010

Cited by 8 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this case, Rosuvastatin with weak anti-hypertensive effect could not alter significantly the peripheral resistance and the resultant SBP. This result was consistent with the report by Prandin MG that the confounding factors, such as age and baseline SBP, might influence the blood pressure of each individual [24].…”

Section: Discussionsupporting

confidence: 93%

Rosuvastatin‐attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway

Qiu

Zhang

Fan

et al. 2012

J Cellular Molecular Medi

View full text Add to dashboard Cite

There are controversies concerning the capacity of Rosuvastatin to attenuate heart failure in end-stage hypertension. The aim of the study was to show whether the Rosuvastatin might be effective or not for the heart failure treatment. Twenty-one spontaneously hypertensive rats (SHRs) aged 52 weeks with heart failure were randomly divided into three groups: two receiving Rosuvastatin at 20 and 40 mg/kg/day, respectively, and the third, placebo for comparison with seven Wistar-Kyoto rats (WKYs) as controls. After an 8-week treatment, the systolic blood pressure (SBP) and echocardiographic features were evaluated; mRNA level of B-type natriuretic peptide (BNP) and plasma NT-proBNP concentration were measured; the heart tissues were observed under electron microscope (EM); myocardial sarcoplasmic reticulum Ca 2+ pump (SERCA-2) activity and mitochondria cytochrome C oxidase (CCO) activity were measured; the expressions of SERCA-2a, phospholamban (PLB), ryanodine receptor2 (RyR2), sodium-calcium exchanger 1 (NCX1), Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) and protein phosphatase inhibitor-1 (PPI-1) were detected by Western blot and RT-qPCR; and the total and phosphorylation of protein kinase Ca/b (PKCa/b) were measured. Aged SHRs with heart failure was characterized by significantly decreased left ventricular ejection fraction and left ventricular fraction shortening, enhanced left ventricular end-diastolic diameter and LV Volume, accompanied by increased plasma NT-proBNP and elevated BNP gene expression. Damaged myofibrils, vacuolated mitochondria and swollen sarcoplasmic reticulum were observed by EM. Myocardium mitochondria CCO and SERCA-2 activity decreased. The expressions of PLB and NCX1 increased significantly with up-regulation of PPI-1 and down-regulation of CaMKII, whereas that of RyR2 decreased. Rosuvastatin was found to ameliorate the heart failure in aged SHRs and to improve changes in SERCA-2a, PLB, RyR2, NCX1, CaMKII and PPI-1; PKCa/b2 signal pathway to be suppressed; the protective effect of Rosuvastatin to be dose dependent. In conclusion, the heart failure of aged SHRs that was developed during the end stage of hypertension could be ameliorated by Rosuvastatin.Keywords: spontaneously hypertensive rat heart failure Rosuvastatin protein kinase Ca/b2 sarcoplasmic reticulum calcium pump phospholamban ryanodine receptor2 sodium-calcium exchanger

show abstract

Section: Discussionsupporting

confidence: 93%

Rosuvastatin‐attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway

Qiu

Zhang

Fan

et al. 2012

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…In this case, Rosuvastatin, possessing weak anti‐hypertensive effect, could not alter significantly the peripheral resistance and the resultant SBP. Prandin MG also pointed out that the confounding factors, such as age and baseline SBP, might influence the blood pressure of each individual . Thus, differences in animal models, statins and experimental protocols might account for these divergent findings.…”

Section: Discussionmentioning

confidence: 99%

The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end‐stage hypertension in rats

Zhang

et al. 2012

J Cellular Molecular Medi

View full text Add to dashboard Cite

End-stage hypertensive heart disease is an increasing cause of cardiac mortality. Therefore, the current study focused on the cardiac remodelling from hypertrophy to fibrosis in old-aged spontaneously hypertensive rats (SHRs), and explored the therapeutic effects of Rosuvastatin and its possible mechanism(s) of action. Spontaneously hypertensive rats at age 52 weeks were randomly divided into three groups, the first two to receive Rosuvastatin at a dose of 20 mg/kg/day and 40 mg/kg/day, respectively, and the third to receive placebo, which was to be compared with Wistar-Kyoto as controls. After 2-month treatment, SBP, heart to body weight ratio (HW/BW%) and echocardiographic features were evaluated, followed by haematoxylin and eosin and Masson trichrome staining in conjunction with qPCR of foetal gene expressions. Transferase-mediated dUTP nick-end labelling assay and immunofluorescent labelling for active caspase-3 were used to detect the apoptotic cardiomyocytes. Signaling pathways involved were examined by using western blot. Old-aged SHR developed end-stage hypertensive heart disease characterized by significant enhancement of HW/BW%, LVAWd and LVPWd, and decreased LVEF and LVFS, accompanied by cardiomyocytes enlargement and fibrosis along with activation of foetal gene programme. Cardiac apoptosis increased significantly during the transition process. Rosuvastatin reduced hypertrophy significantly via AT1 Receptor-PKCβ2/α-ERK-c-fos pathway; protected myocardium against apoptosis via Akt-FOXO1, Bcl-2 family and survivin pathways and consequently suppressed the caspase-3 activity. The present study revealed that old-aged SHRs developed cardiac remodelling from hypertrophy to fibrosis via cardiac apoptosis during the end stage of hypertensive heart disease. These pathological changes might be the consequence of activation of AT1 Receptor-PKCβ2/α-ERK-c-fos and AKT-FOXO1/Bcl-2/survivin/Caspase3 signaling. Rosuvastatin effectively attenuated the structural changes by reversing the signaling transductions involved.

show abstract

“…For example, the second National Health and Nutrition Examination Survey (NHANES II) data from the United States reported that 90% of individuals with prehypertension had at least one other cardiovascular risk factor . In addition, the Women's Health Initiative study showed that the prevalence of diabetes mellitus and hypercholesterolemia increased concordantly with BP, and prospective studies have confirmed that reducing BMI and lipid levels can decrease prehypertension . Therefore, the control of obesity, diabetes, and dyslipidemia are important prehypertension prevention strategies.…”

Section: Discussionmentioning

confidence: 99%

Prehypertension in Rural Northeastern China: Results From the Northeast China Rural Cardiovascular Health Study

Zhao

Guo

Zheng

et al. 2014

J of Clinical Hypertension

View full text Add to dashboard Cite

using a multistage clustering method to select a representative sample of individuals (≥35 years old), resulting in a study population of 11,576 adults. Prehypertension was defined as a systolic blood pressure (BP) in the range of 120 mm Hg to 139 mm Hg and/or a diastolic BP between 80 mm Hg and 89 mm Hg according to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). The results showed that the meanAEstandard deviation systolic and diastolic BP values for the entire population were 141.8AE23.5 mm Hg and 82.1AE11.8 mm Hg, respectively. Among the whole population, 35.1% of men and 32.5% of women were prehypertensive. Multiple logistic regression analysis showed that high body mass index, advanced age, alcohol consumption, diabetes, high triglyceride and lowdensity lipoprotein cholesterol levels, and elevated diet score were risk factors for prehypertension. This study indicates that there is a high prevalence of prehypertension in rural China and confirms the importance of healthy lifestyles-including the control of obesity, diabetes, and dyslipidemia-to decrease the incidence of prehypertension.

show abstract

Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise

Cited by 8 publications

References 31 publications

Rosuvastatin‐attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway

Rosuvastatin‐attenuated heart failure in aged spontaneously hypertensive rats via PKCα/β2 signal pathway

The therapeutic effect of Rosuvastatin on cardiac remodelling from hypertrophy to fibrosis during the end‐stage hypertension in rats

Prehypertension in Rural Northeastern China: Results From the Northeast China Rural Cardiovascular Health Study

Contact Info

Product

Resources

About